Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP
HUTCHMED's medicine got special FDA approval status for a rare blood disease. This means fewer competitors could sell similar drugs for seven years if approved.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.